Jennings, AU
Aaron Benjamin Jennings, Broadbeach Waters AU
Patent application number | Description | Published |
---|---|---|
20150223551 | FOOTWEAR - The present invention generally relates to footwear. The footwear comprising a sole able to be located under the foot of a user, the sole having three holes passing through the sole and a front channel and first and second rear channels formed in an underside of the sole. The footwear also consists of a strap able to locate the sole under the foot of a user, the strap having three plugs; and wherein each of the three holes in the sole are aligned with respective channels so as to allow the three respective plugs to pass through each respective hole to be located in each of the respective channels to secure the strap to the sole. | 08-13-2015 |
Cameron Victor Jennings, Doncaster AU
Patent application number | Description | Published |
---|---|---|
20100068762 | NOVEL NUCLEIC ACID MOLECULES - The present invention relates to a novel nucleic acid molecule encoding an amino acid sequence, which is capable of forming a cyclic structure. Cyclization may occur within a cell or cell membrane, or linear forms of the molecules may be circularised or partially circularised, in vitro using isolated enzyme systems or chemical means. The cyclised amino acid sequence is generally in the form of a stabilized folded structure such as acyclic knotted peptide, polypeptide or protein or functional equivalent. The nucleic acid molecules and cyclic and linear peptides are useful inter alia in the generation of molecules having animal or plant therapeutic properties, as well as in a range of diagnostic, industrial and agricultural, including horticultural, applications. Of particular importance is the use of these molecules in the protection of plants, such as crop plants, from pest and/or pathogen infestation. | 03-18-2010 |
Michael P. Jennings, Brisbane AU
Patent application number | Description | Published |
---|---|---|
20100010211 | Vaccine - The invention relates to a vaccine for the treatment of disease caused by | 01-14-2010 |
20100015175 | Vaccine - The invention relates to a vaccine for the treatment of disease caused by | 01-21-2010 |
20100016560 | Vaccine - The invention relates to a vaccine for the treatment of disease caused by | 01-21-2010 |
Michael Paul Jennings, St. Lucia AU
Patent application number | Description | Published |
---|---|---|
20090068216 | MODIFIED SURFACE ANTIGEN - Novel proteins that constitute modified forms of a | 03-12-2009 |
Michael Paul Jennings, Carina AU
Patent application number | Description | Published |
---|---|---|
20090270591 | NOVEL SURFACE ANTIGEN - The invention provides a novel surface polypeptide from | 10-29-2009 |
20100331537 | NOVEL SURFACE ANTIGEN - The invention provides a novel surface polypeptide from | 12-30-2010 |
20120123093 | NOVEL SURFACE ANTIGEN - The invention provides a novel surface polypeptide from | 05-17-2012 |
20130085262 | NOVEL SURFACE ANTIGEN - The invention provides a novel surface polypeptide from | 04-04-2013 |
Michael Paul Jennings, Brisbane AU
Patent application number | Description | Published |
---|---|---|
20100010210 | Vaccine - The invention relates to a vaccine for the treatment of disease caused by | 01-14-2010 |
20110171234 | Vaccine - The invention relates to a vaccine for the treatment of disease caused by | 07-14-2011 |
20110262476 | MUTANT BACTERIAL GLYCOPROTEINS AND USES THEREOF - The present invention relates to the use of mutant glycoproteins from pathogenic bacteria lacking one or more phosphorylcholine and/or glycosylation post-translational modifications as immunogens. These post-translational modifications act as masking structures that elicit an immune response which does not confer protection on an infected individual. The removal or modification of these masking structures alters the protein such that it elicits a stronger immune response to the protein and/or the bacterial pathogen. Particular examples are pilin proteins and nitrite reductase glycoproteins of | 10-27-2011 |
20120121646 | Vaccine - The invention relates to a vaccine for the treatment of disease caused by | 05-17-2012 |
20140050731 | Vaccine - The invention relates to a vaccine for the treatment of disease caused by | 02-20-2014 |
Michael Paul Jennings, Manly AU
Patent application number | Description | Published |
---|---|---|
20090068229 | MODIFIED SURFACE ANTIGEN - Novel proteins that constitute modified forms of a | 03-12-2009 |
20130136762 | MODIFIED SURFACE ANTIGEN - Novel proteins that constitute modified forms of a | 05-30-2013 |
20130196901 | Neisseria Porin Protiens - PorA constructs are provided which have one or more disrupted variable regions created by insertion of entire conserved regions or conserved region amino acids. The highly immunogenic variable regions of PorA are responsible for eliciting strain-specific immune responses that are not broadly protective, so disruption of the variable regions directs the immune response against conserved region epitopes to effectively immunize against a broader spectrum of | 08-01-2013 |
Philip Jennings, Warrawee AU
Patent application number | Description | Published |
---|---|---|
20110262445 | ANTI-IL-12/IL-23 ANTIBODIES - The present invention provides an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80) and the antibody inhibits the binding of human IL-12 to human IL-12R β2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12Rβ1. | 10-27-2011 |
Philip A. Jennings, Macquarie Park AU
Patent application number | Description | Published |
---|---|---|
20130280246 | Humanized Antibodies with Anti-Tumor Activity - The present invention provides humanised antibodies and binding domains thereof with anti-tumour activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumour cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumour models. | 10-24-2013 |
Philip A. Jennings, Warrawee AU
Patent application number | Description | Published |
---|---|---|
20080255343 | CHIMERIC ANTIBODIES - The present invention provides a chimeric antibody or an antigen-binding portion thereof. The antigen-binding portion comprises at least two complementarity determining regions (CDR) and at least three framework regions, wherein at least one CDR is a New World primate CDR | 10-16-2008 |
20090286962 | CHIMERIC ANTIBODIES WITH PART NEW WORLD PRIMATE BINDING REGIONS - The present invention provides a chimeric antibody polypeptide comprising an antigen binding site, wherein the antigen binding site comprises a human variable domain having at least one New World Primate CDR. | 11-19-2009 |
20100297134 | HUMANISED ANTIBODIES WITH ANTI-TUMOUR ACTIVITY - The present invention provides humanised antibodies and binding domains thereof with anti-tumour activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumour cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumour models. | 11-25-2010 |
20110044979 | DOMAIN ANTIBODY CONSTRUCT - The present invention provides a domain antibody construct which binds to human TNF-α, with the construct comprising: | 02-24-2011 |
20110237780 | ANTI-INFLAMMATORY DAB - The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-α, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein said variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate. | 09-29-2011 |
20130040383 | Nucleic acid molecules encoding anti-inflammatory domain antibodies - The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-α, the dAb comprising an immunoglobulin heavy or light chain variable domain, comprising at least one complementarity determining region (CDR) having a sequence derived from a New World primate. | 02-14-2013 |
Philip Anthony Jennings, Warrawee, New South Wales AU
Patent application number | Description | Published |
---|---|---|
20100040620 | ANTI-CANCER ANTIBODIES AGAINST LEWISy AND LEWISb ANTIGENS - The present invention provides a binding complex comprising antibodies or antigen-binding fragments which bind to both Lewis | 02-18-2010 |
Philip Anthony Jennings, New South Wales AU
Patent application number | Description | Published |
---|---|---|
20110319597 | VARIANT DOMAIN ANTIBODIES - The present invention relates to domain antibodies which have modified framework regions such that the potency or level of binding of the domain antibody is improved. In particular the present invention relates to domain antibodies which bind TNFa in which changes have been made to framework sequences and to constructs including these domain antibodies. | 12-29-2011 |
Philip Anthony Jennings, Warrawee AU
Patent application number | Description | Published |
---|---|---|
20140086922 | ANTI-IL-12/IL-23 ANTIBODIES - Provided herein is an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80), and the antibody inhibits the binding of human IL-12 to human IL-12Rβ2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12Rβ1. | 03-27-2014 |
20140255302 | ANTIBODIES AGAINST TL1a AND USES THEREOF - The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins. | 09-11-2014 |